Kornimate/medical-research-clean huggingface dataset:
spectral analysis of central venous pressure waveform

Conditions: Donor Hepatectomy; Central Venous Catheter; Hypovolemia

Summary: the use of central venous pressure has been abandoned for the assessment of intravascular volume status. the dynamic fluctuation of central venous pressure according to heart rate is quantitatively measured by spectral analysis of the central venous pressure waveform. its clinical utility in the assessment of intravascular volume status is investigated.

the use of central venous pressure, which is one of the static preload indices, has been abandoned for the assessment of intravascular volume status because of its unreliability. the static preload indices have been replaced with dynamic preload indices, such as stroke volume variation or pulse pressure variation because the dynamic preload indices reliably predict fluid responsiveness and perform better than the static preload indices. however, the periodic component of central venous pressure, which goes with cardiac cycles, has not been investigated. the power corresponding to heart rate from spectral analysis of central venous pressure waveform represents the extent of the dynamic fluctuation of central venous pressure and is assumed to reflect intravascular volume status. it is hypothesized that the spectral power of central venous pressure corresponding to heart rate represents intravascular volume status.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status 1 * scheduled for donor hepatectomy under general anesthesia exclusion criteria: * arrhythmia * valvular heart disease * coronary artery disease * cerebrovascular disease * hypertension * diabetes mellitus * renal insufficiency * pulmonary problems * any type of liver disease * body mass index greater than 35 kg/m2 * human immunodeficiency virus infection * psychosocial problems * electrolyte imbalance * reoperation
eslicarbazepine acetate monotherapy long term study

Conditions: Epilepsy

Summary: this is a long term, open-label, safety extension study in subjects with partial onset seizures.

this is a long term, multicenter, open-label, safety extension study in subjects with partial onset seizures who have just completed, discontinued, or exited the 18-week treatment phase of protocols 093-045 or 093-046. the initial study duration is 1 year with the option of continuing study drug treatment post 1 year until a subject discontinues study, the study drug becomes clinically available in the subject's locale, or the sponsor terminates the study drug clinical development program. this study was previously posted by sepracor inc. in october 2009, sepracor inc. was acquired by dainippon sumitomo pharma., and in october 2010, sepracor inc's name was changed to sunovion pharmaceuticals inc.

Eligibility criteria:
subject inclusion/exclusion criteria: * subject who completed, exited, or discontinued for reasons other than safety from the 18-week treatment phase of protocols 093-045 or 093-046 and are willing to continue participation in this study are eligible. subject must have completed at least the first 3 weeks of the 18-week double-blind treatment period of protocols 093-045 or 093-046 to be eligible. * subject must give written informed consent prior to participation in the study. for subjects \<18 years of age, the informed consent must be signed by the subject's parent or legal guardian, and, when appropriate and/or required by state or local law, minor subjects must give written informed assent prior to participation in the study. all subjects must sign privacy authorization form, if applicable. all females of child bearing potential (≤65 years of age) must also sign the "women of childbearing potential" addendum. * subjects must, in the opinion of the investigator (with consultation with medical monitor as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation. * if female subject, must continue the accepted method of birth control defined in protocols 093-045 or 093-046 for the duration of this study as well * criterion for continuation into the post 1 year part of study: for subjects to continue into the post 1 year part of the study, subjects must, in the opinion of the investigator (with consultation with medical monitor, as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation.

Keywords: seizures epilepsy anticonvulsant monotherapy epilepsy with simple or complete partial onset seizures
international multicenter mycotic aneurysm aorto-iliac study

Conditions: Mycotic Aneurysm; Aortic Diseases

Summary: the term mycotic aneurysm (ma) is commonly used to describe all infected aneurysms. although mas are believed to occur uncommonly, the true incidence is difficult to determine and is probably underestimated since mas can be asymptomatic and are diagnosed only at autopsy. in an autoptic study, mycotic aortic aneurysms (maas) were reported in 3.3% of all detected aneurysms. the incidence of infected aneurysms of the aorta and iliac arteries ranges from 0.6% to 1.3%. a recent literature review of the management of maas showed that therapeutic strategies are multiple, including open surgical repair (osr) in the majority of cases, endovascular aortic repair (evar), which increased over the last decade, and medical treatment alone for patients unfit for any aortic repair in a very limited part. following the unfavorable prognosis towards rupture and since the medical treatment alone in mycotic aneurysms has shown mortality of almost 100%, surgical treatment is generally the preferred option. surgical treatment includes both open and endovascular surgery. the latter is less invasive than conventional surgery but does not involve resection of the infected tissue and is therefore associated with an increased risk of sepsis and prosthesis infection. the gold standard is still open surgery, including extra-anatomic reconstruction and in situ repair, with different type of vascular graft. this is a multicenter retrospective observational study. it will examine all patients undergoing surgical treatment of mycotic aortic-iliac aneurysms and in situ reconstruction at the participating centers.


Eligibility criteria:
inclusion criteria: * primary mycotic aorto-iliac aneurysm who underwent in situ repair exclusion criteria: * patient with vascular graft infections; * patient with secondary aorto-enteric fistula.
nudging high-acuity emergency department patients to schedule a follow-up visit

Conditions: Emergency Service, Hospital

Summary: the goal of this campaign is to reduce unnecessary emergency department (ed) visits by encouraging patients with high acuity visits to follow up with an appropriate primary care provider (pcp) or specialist and therefore obtain appropriate care outside of the ed. in this campaign, patients will be assigned to receive or not receive outreach following ed discharge that is aligned with the goal. outreach will occur via a text message and information added to the patient's after visit summary, and will include a contact number to schedule and hyperlink to allow self-scheduling. the study will assess whether ed use differs across patients in different outreach conditions. it will also examine whether patients followed through on the calls to action in the messages differently across conditions.

enrollment will conclude when either 7500 participants have been enrolled or after 120 days, whichever occurs first.

Eligibility criteria:
inclusion criteria: * \>= 18 years of age * ed visit rated as high acuity (level l2 or l3) * discharged from ed in past 24 hours * attributed to a geisinger pcp in community medicine service line exclusion criteria: * have an appointment scheduled within 7 days following discharge with a primary care provider or specialist * institutionalized * cannot be contacted via the communication modality being used in the study (i.e., sms), due to insufficient/missing contact information in the electronic health record or because the patient opted out * admitted to hospital * eloped from ed * left ed without being seen * deceased prior to messaging
menthol, inflammation, and nicotine transition study

Conditions: Cigarette Smoking; Inflammatory Response

Summary: this study will focus on examining the potential impact of menthol flavoring in cigarettes on biomarkers of systemic inflammation as a subclinical indicator of cardiovascular disease risk.

the goal of this study is to examine how switching from menthol (mc) to non-menthol (nmc) cigarette smoking may impact biomarkers of systemic inflammation, smoking behavior, and subjective responses related to smoking. mc smokers (n=68) will be recruited for a five-week study, with one-week of baseline of mc smoking (phase 1), followed by four weeks of switching to study-provided, brand-matched nmcs (phase 2). biomarkers of systemic inflammation and tobacco exposure will be analyzed from blood samples before, during, and after switching for four weeks (baseline, week 1, week 3, and week 5). ecological momentary assessment methods will also be gathered to measure patterns of smoking and smoking-related subjective responses (affect, craving).

Eligibility criteria:
inclusion criteria * men and women between 21-85 years old * currently uses menthol cigarettes * daily smoking rate of ≥5 cigarettes/day for ≥1 year * currently own and regularly use an ios/android smartphone device able to download the lifedata application * able to read and communicate fluently in english exclusion criteria * currently pregnant or breastfeeding * actively trying to quit smoking * current heavy alcohol use * frequent use of non-menthol cigarettes, other smoking products, or illicit substances * history of severe medical/psychiatric condition or treatment
investigation of the putative correlation between involuntary psoas activity during passive flexion of the trunk at the hips

Conditions: Lower Back Pain

Summary: passive flexion of the trunk (relative to the legs) may be accompanied by contraction of the psoas muscles, even when the subject has been told not to contract any muscles. the psoas contraction is involuntary and cannot be controlled by the subject. this lack of passivity might be concomitant with lower back pain: the impairment may be present when lower back pain is present and/or absent when lower back pain is absent. the study's primary objective is thus to determine the sensitivity and/or specificity of a clinical test for impaired hip flexor passivity in cases of lower back pain during passive flexion of the trunk (from the supine position,). the secondary objective is to show that a negative test (after administration of correcting measures) is correlated with a decrease in pain (i.e. pain intensity and the functional repercussions of pain).


Eligibility criteria:
inclusion criteria: * age between 18 and 30 * social security coverage * ability to understand the study's objectives, procedures and risks and to provide informed, written consent * having been informed about the results of the prior clinical examination. exclusion criteria: * past or concomitant infectious or cancerous diseases of the spine * vertebral osteosynthesis * acute neck or arm pain (recurrent dislocations of the glenohumeral joint, trauma in the previous 12 months, etc.) * lower back pain with irradiation of pain below the buttocks * known specific lower back pain or pain for which a differential diagnosis suggests an inflammatory, traumatic, cancerous or infectious cause * subjects under legal guardianship * known pregnancy * simultaneous participation in another biomedical research study of a drug or medical device.

Keywords: reliability clinical test physical therapy
day-case closure of loop ileostomy in rectal cancer

Conditions: Ileostomy Closure in Rectal Cancer

Summary: the aim of this study is to investigate if day-case closure of ileostomy is feasible and safe.

for all patients that match the inclusion criteria a registration-protocol is completed. then the patients are operated and a surgery-protocol is completed. the patients are observed for maximum 24 h and discharged if they meet the discharge-criteria. 30 days post-operative the investigators do a follow-up of complications.

Eligibility criteria:
inclusion criteria: * adults not older than 80 planed for closure of ileostomy * the patient should not have had the ileostomy for more than 1 year * informed written consent should be given * the patient should have a phone * should have an adult supervision at home for the first 24 hours after discharge * american society of anesthesiologists (asa) classification 1-2 exclusion criteria: * asa classification 3 and above * the pre-operative investigation have shown anastomosis leakage or stricture * dementia or other cognitive dysfunction * the need of an interpreter * patients assessed not being able to manage themselves at home post-operative * insulin treated diabetes * coagulopathy * other organ dysfunction * bleeding more than 300 ml * if converted to laparatomy * other intraoperative difficulties leading to suspected increased risk of complication discharge criteria: * stable vital parameters regarding circulation and respiration * no sign of bleeding * pain relief possible through per oral administration * emptied urinary bladder * able to maintain per oral nutrition * mobilization possible * obtained oral and written information about symptoms of sepsis and bowel obstruction * obtained telephone number of a contact-nurse * obtained time for wound-inspection at the surgical unit
the role of extracellular dna (ecdna) in the occurrence and development of gastric

Conditions: Gastric Cancer; Precancerous Lesion of Digestive Tract; Extrachromosomal DNA

Summary: ecdna is almost non-existent in normal cells, but exists in nearly half of human cancer cells, indicating that studying such abnormal dna is of great significance for our understanding of tumor formation and evolution. the changes in ecdna expression in intestinal type gastric cancer may be closely related to the occurrence and development of gastric cancer. dynamic monitoring of changes in ecdna expression in the gastric mucosa may help predict the occurrence of gastric cancer and guide subsequent treatment. by collaborating with multiple endoscopic centers to conduct gastroscopy biopsies on patients with gastric precancerous lesions, we aim to further explore the role of ecdna in the occurrence and development of gastric cancer through continuous follow-up.


Eligibility criteria:
inclusion criteria: 1. age: 18-80 years old; 2. patients who plan to undergo gastroscopy at the endoscopic center and patients who undergo surgical treatment for gastric adenocarcinoma; 3. endoscopy doctors believe that pathological biopsy is necessary to clarify the pathological diagnosis; 4. no serious diseases or other systemic malignancies in terms of physical and mental health; 5. more than one item of non atrophic gastritis, atrophic gastritis, intestinal metaplasia, heterogeneous hyperplasia (low grade intraepithelial neoplasia and high grade intraepithelial neoplasia), and gastric adenocarcinoma; 6. sign an informed consent form; exclusion criteria： 1. pathological results indicate other malignant tumors of the stomach, such as stromal tumors and lymphoma; 2. the patient and their family members do not agree to use the specimen for later research projects; 3. before gastroscopy or surgery, neoadjuvant therapy or combined with other malignant tumors; 4. non r0 resected gastric cancer patients; 5. pregnant or lactating women; 6. have a history of drug abuse such as alcohol and tobacco.
early revascularization in stable ischemic heart disease using p.e.t. imaging

Conditions: Ischemic Heart Disease

Summary: to compare the impact of revascularization and optimal medical treatment (omt) on the extent of severely reduced coronary flow capacity in stable ischemic heart disease.

the initial positron emission tomography (pet) scan will be performed as part of clinical practice. if the patient is a potential candidate for the study, the patient will be screened for inclusion and exclusion criteria. after being informed about the study potential risks, all patients giving written informed consent will be randomized into one of two groups: urgent revascularization combined with optimal medical treatment (omt) or omt with delayed revascularization. following the initial pet scan, randomization and treatment, each group will undergo a second pet scan at the 3-4 month mark and a third pet scan at the one year mark. some crossover may occur with the two groups. the omt without urgent revascularization patients will remain in that group, if clinically stable, up to three months. at their first follow-up visit (day 105±20), patients will be offered the option of continued medical treatment or elective revascularization consistent with informed patient preference and clinical judgement. patients, in consultation with their physicians, may elect to undergo revascularization at any time thereafter.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. stable ischemic heart disease as determined by an investigator. 3. areas of severely reduced cfc or relative stress images on the rentrop diagnostic pet mpi consistent with clinical judgement as follows: • pets with a defect on rest relative images of ≤60% of max for ≤5% of lv (no large scar) plus: i. ≥2% of lv with cfcblue\* or ii. ≥10% of lv with cfcgreen\* plus at least one pixel with cfcblue\* \*cfcblue is defined as a dipyridamole induced stress flow ≤ 0.83 ml/min/g of myocardium and a cfr ≤ 1.27. cfcgreen is defined as a dipyridamole induced stress flow ≤1.09 and \>0.83 ml/min/g of myocardium and a cfr ≤1.60 and \>1.27. 4. willing to comply with the follow-up schedule of the trial. 5. subject must sign the informed consent in english or spanish. exclusion criteria: 1. any conditions that may compromise or prevent the necessary imaging requirements. 2. less than one-year life expectancy. 3. currently pregnant or planning to become pregnant during the course of the study. 4. any other issues that the investigator believes may interfere with treatment or follow-up. 5. subjects who lack capacity to consent for themselves.

Keywords: positron emission tomography pet scan
optical frequency domain imaging (ofdi) in dermatology

Conditions: Port Wine Stain

Summary: this is a pilot exploratory study. the goal of this study is to evaluate a new imaging tool, optical frequency domain imaging (ofdi), to reveal the microvascular morphology of capillary malformations.

the subject population will be composed of 8 subjects meeting the inclusion and exclusion criteria. up to 8 subjects may be enrolled for the study after obtaining written, informed consent prior to participation in the study. recruitment will be performed by direct advertisement to subjects inside and outside brigham and women's hospital (bwh), including the bwh dermatology clinic. the study patients will be managed using standard of care in practice at the bwh dermatology clinic. the study will be conducted at brigham and women's hospital dermatology clinic where the pulsed dye laser is housed. patients referred to the bwh dermatology clinic will be eligible for recruitment. the study nurse/staff involved in patient enrollment will be familiar with the care of this type of patients. the medical history of these patients will be examined to determine if the study eligibility requirements are met. if the patient is selected as a potential subject, a letter will be sent about 7 days prior to their scheduled exam to ask if they would care to participate. this time frame should allow time for the patient to consider study participation.

Eligibility criteria:
inclusion criteria: 1. subjects: fitzpatrick skin type i-vi, of either gender 2. subjects must be between 18 and 80 years of age. 3. subjects must have a not previously treated port wine stain of at least 1 cm2 on either a) trunk and extremities or b) face and neck. 4. subjects are scheduled for pld treatment of the port wine stain 5. subjects must be willing and able to comply with all follow-up requirements. exclusion criteria: 1. subjects must not have active localized or systemic infections 2. subjects must not be on aspirin. 3. subjects must not be currently taking accutane or be off accutane for less than 6 months prior to initiation of the study. 4. subjects must not be participating in potentially confounding research; e.g. a clinical study of any other unapproved investigational drug or device. 5. subjects must not be pregnant or planning to become pregnant over the course of the study.

Keywords: port wine stain
a study of the safety and effectiveness of infliximab in patients with plaque-type psoriasis

Conditions: Psoriasis; Parapsoriasis

Summary: the purpose of the study is to evaluate the safety and effectiveness of scheduled and as needed treatment of psoriasis with infliximab. infliximab (remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

this is a phase iii, multicenter, randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), placebo-controlled trial evaluating the effectiveness and safety of scheduled and as needed treatment with infliximab in patients with plaque-type psoriasis. this study will also help determine the way to use infliximab in treating patients with psoriasis. safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures. patients will receive infusions of either placebo, 3mg/kg or 5 mg/kg infliximab (remicade) at weeks 0, 2, 6 14, 18, 22, 26, 30, 34, 38, 42 and 46. patients receive either 3mg/kg, 5 mg/kg or placebo infusions at week 0, 2, and 6. the 3mg/kg and 5 mg/kg infliximab groups then receive either every 8 week infusions or infusions as needed when their psoriasis is less than 75% improved from baseline. the placebo patients begin infliximab at week 16, 18 and 22 followed by every 8 week infusions.

Eligibility criteria:
inclusion criteria: * patients with diagnosis of plaque-type psoriasis for at least 6 months * patients with plaque-type psoriasis covering at least 10% of the body exclusion criteria: * patients with nonplaque forms of psoriasis * patients who have current drug-induced psoriasis * patients who are pregnant, nursing, or planning pregnancy (both men and women) within 18 months of enrollment * patients who had any previous treatment with infliximab or any therapeutic agent targeted at reducing tumor necrosis factor

Keywords: plaque-type psoriasis psoriasis drug safety drug efficacy maintenance therapy induction therapy remicade